Bank Of America Corp Chemo Centryx, Inc. Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$22.17 - $51.8 $3.42 Million - $7.99 Million	154,318 Added 75.01%	360,036 $18.6 Million
Q2 2022 Aug 12, 2022	SELL	$15.36 - $27.51 $1.47 Million - $2.64 Million	-95,804 Reduced 31.77%	205,718 $5.1 Million
Q1 2022 May 16, 2022	BUY	$22.22 - $39.12 $4.99 Million - $8.79 Million	224,627 Added 292.12%	301,522 $7.56 Million
Q4 2021 Feb 08, 2022	BUY	$18.38 - $40.5 $106,787 - $235,305	5,810 Added 8.17%	76,895 $2.8 Million
Q3 2021 Nov 15, 2021	BUY	$13.18 - $19.83 $587,709 - $884,239	44,591 Added 168.31%	71,085 $1.22 Million
Q2 2021 Sep 13, 2021	BUY	$9.59 - $50.88 $254,077 - $1.35 Million	26,494 New	26,494 $354,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.